Is Edwards Lifesciences (EW) overvalued or fairly valued?

MarketChacha shows Edwards Lifesciences's valuation in context — a forward P/E of about 25.1, a price-to-book of about 4.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of Edwards Lifesciences (EW)?

Edwards Lifesciences last traded at $84.42 (-0.2% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Edwards Lifesciences

EW · NYSE · Healthcare · United States

$84.42-0.2%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 5:18 PM

Snapshot

TickerEW

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees16,000

HeadquartersIrvine, United States

Market cap$48.6B

P/B4.7

Volume1.5M

Websitewww.edwards.com

Filings tracked0

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.2%
Institutions94.2%
Public & other5.6%

1,879 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.9.13%
Vanguard Capital Management LLC6.55%
Vanguard Portfolio Management LLC4.59%
State Street Corporation4.57%
Wellington Management Group, LLP3.82%
JPMORGAN CHASE & CO3.78%
Bank Of New York Mellon Corporation2.91%
FMR, LLC2.52%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

What's expected next

Next quarter

Rev $1.7B · EPS 0.75

Est. earnings growth +11.4%

Next fiscal year

Rev $7.4B · EPS 3.36

Est. earnings growth +11.8%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$72.3052-wk range$96.29

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Ask MarketChacha about EW

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.